The probability of revision sinus surgery including removing nasal polyps is higher if the patient has asthma or is on ...
News Medical on MSN3d
Asthma and antibiotic use increase the likelihood of revision sinus surgeryThe probability of revision sinus surgery including the removal of nasal polyps is higher if the patient has asthma or is on antibiotics at the time of their initial surgery. However, higher age was ...
HealthDay on MSN1d
Baseline Characteristics ID Risk for Recurrent Endoscopic Sinus SurgeryTHURSDAY, Feb. 6, 2025 (HealthDay News) -- A few baseline characteristics can predict the need for recurrent endoscopic sinus ...
AstraZeneca has failed in its bid to get US approval for its IL-5 inhibitor Fasenra as a treatment for chronic rhinosinusitis in people with nasal polyps, after the FDA rejected its marketing ...
The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...
Zacks.com on MSN16h
Insmed's NDA for Lung Disease Drug Gets FDA's Priority ReviewThe FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.
Sanofi in partnership with Regeneron to present 24 abstracts across approved and investigational medicines at AAAAI Annual Meeting in San Diego: Paris Friday, February 7, 2025, 12 ...
The global laser-assisted ENT surgery market Share is projected to grow from US$ 254.14 million in 2023 to US$ 513.78 million ...
Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...
A Feature on M&A, VC investment licensing and partnerships focusing on novel targets in autoimmune diseases.
GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback